A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
Parabilis Medicines, Inc.
Arcus Biosciences, Inc.
AstraZeneca
AstraZeneca
UNC Lineberger Comprehensive Cancer Center
University of California, Irvine
City of Hope Medical Center
Institut Bergonié
Merck Sharp & Dohme LLC
Incyte Corporation
Toray Industries, Inc
AIDS Malignancy Consortium
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
ImmunityBio, Inc.
AIDS Malignancy Consortium
Sixth Affiliated Hospital, Sun Yat-sen University
Northwestern University
National Institute of Allergy and Infectious Diseases (NIAID)
St. Petersburg State Pavlov Medical University
AstraZeneca
AIO-Studien-gGmbH
Ziekenhuis Oost-Limburg
Washington University School of Medicine
UNICANCER
National Institutes of Health Clinical Center (CC)
Valerio Therapeutics
National Taiwan University Hospital
National Cancer Institute (NCI)
Uppsala University
Radiation Therapy Oncology Group
GOG Foundation
European Organisation for Research and Treatment of Cancer - EORTC
Sanofi
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
Sanofi